Organization
ProfoundBio
3 clinical trials
1 abstract
Clinical trial
Phase 1/2 Study of PRO1160 in Patients With Renal Cell Carcinoma (RCC), Nasopharyngeal Carcinoma (NPC), or Non-Hodgkin Lymphoma (NHL)Status: Recruiting, Estimated PCD: 2024-04-30
Clinical trial
A Phase 1/2 Study of PRO1107 in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2027-02-01
Clinical trial
Phase 1/2 Study of PRO1184 in Patients With Locally Advanced and/or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2025-10-01
Abstract
Phase 1/2 study of PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors.Org: Mary Crowley Cancer Research, Providence Medical Center, Stephenson Cancer Center University of Oklahoma/Sarah Cannon Research Institute, ProfoundBio, Sarah Cannon Research Institute at Tennessee Oncology, PLLC,